Power to detect selective allelic amplification in genome-wide scans of tumor data

Bioinformatics

Volumn 26, Issue 4, 2009, Pages 518-528

  Dewal, Ninad ^a   Freedman, Matthew L ^b,c   LaFramboise, Thomas ^d   Pe'er, Itsik ^e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77949511314     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btp694     Document Type: Article

References (49)

1. Ahmed, S. et al. (2009) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat. Genet., 41, 585-590.
2. Amos, C.I. et al. (2008) Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet., 40, 616-622.
3. Amundadottir, L.T. et al. (2006) A common variant associated with prostate cancer in European and African populations. Nat. Genet., 38, 652-658.
4. Bentz, M. et al. (1998) Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer, 21, 172-175.
5. Browning, S.R. and Browning,B.L. (2007) Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering, Am. J. Hum. Genet., 81, 1084-1097.
6. Cher, M.L. et al. (1996) Genetic alterations in untreated metastases and androgenindependent prostate cancer detected by comparative genomic hybridization and allelotyping, Cancer Res., 56, 3091-3102.
7. Easton, D.F. et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447, 1087-1093.
8. Ewart-Toland, A. and Balmain, A. (2004) The genetics of cancer susceptibility: from mouse to man. Toxicol. Pathol., 32(Suppl. 1), 26-30.
9. Ewart-Toland, A. et al. (2003) Identification of Stk6/STK15 as a candidate lowpenetrance tumor-susceptibility gene in mouse and human. Nat. Genet., 34, 403-412.
10. Fletcher, O. et al. (2008) Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol. Biomarkers Prev., 17, 702-705.
11. Freedman, M.L. et al. (2006) Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc. Natl Acad. Sci. USA, 103, 14068-14073.
12. Gudmundsson, J. et al. (2007) Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet., 39, 631-637.
13. Huang, S.F. et al. (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res., 10, 8195-8203.
14. Hung, R.J. et al. (2008) A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature, 452, 633-637.
15. Iafrate, A.J. et al. (2004) Detection of large-scale variation in the human genome. Nat. Genet., 36, 949-951.
16. Jones, A.V. et al. (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet., 41, 446-449.
17. Joos, S. et al. (1995) Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Genes Chromosomes Cancer, 14, 267-276.
18. Kallioniemi, A. et al. (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science, 258, 818-821.
19. Kilpivaara, O. et al. (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat. Genet., 41, 455-459.
20. Knudson, A.G. Jr. (1971) Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA, 68, 820-823.
21. Komura, D. et al. (2006) Genome-wide detection of human copy number variations using high-density DNA oligonucleotide arrays. Genome Res., 16, 1575-1584
22. Korn, J.M. et al. (2008) Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat. Genet., 40, 1253-1260.
23. Korn, W.M. et al. (1999) Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer, 25, 82-90.
24. Laframboise, T. et al. (2007) PLASQ: a generalized linear model-based procedure to determine allelic dosage in cancer cells from SNP array data. Biostatistics, 8, 323-336.
25. Lynch, T.J. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 350, 2129-2139.
26. Miki et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66-71.
27. Nagase, H. et al. (2003) Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice. Cancer Res., 63, 4849-4853.
28. Nannya, Y. et al. (2005)Arobust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res., 65, 6071-6079.
29. Nomura, M. et al. (2007) Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med., 4, e125.
30. Nowell, P.C. (1976) The clonal evolution of tumor cell populations, Science, 194, 23-28.
31. Olayioye, M.A. et al. (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J., 19, 3159-3167.
32. Olcaydu, D. et al. (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat. Genet., 41, 450-454.
33. Paez, J.G. et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-1500.
34. Pao, W. et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA, 101, 13306-13311.
35. Paris, P.L. et al. (2004) Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum. Mol. Genet., 13, 1303-1313.
36. Shigematsu, H. and Gazdar, A.F. (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer, 118, 257-262.
37. Shigematsu, H. et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst., 97, 339-346.
38. Slamon, D.J. et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182.
39. Solinas-Toldo, S. et al. (1997) Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer, 20, 399-407.
40. Song, H. et al. (2009) Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Hum. Mol. Genet., 18, 2297-2304.
41. Spielman, R.S. et al. (1993) Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am. J. Hum. Genet., 52, 506-516.
42. Sun, J. et al. (2007) DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate, 67, 692-700.
43. Tam, I.Y. et al. (2009) Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol. Cancer Ther., 8, 2142-2151.
44. Thorgeirsson, T.E. et al. (2008) A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature, 452, 638-642.
45. Tomlinson, I. et al. (2007) A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat. Genet., 39, 984-988.
46. Wooster, R. et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature, 378, 789-792.
47. Zanke, B.W. et al. (2007) Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet., 39, 989-994.
48. Zhang, X.T. et al. (2005) The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann. Oncol., 16, 1334-1342.
49. Zhao, X. et al. (2005) Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res., 65, 5561-5570.